Klee Justin B.

Co-Chief Executive Officer

Klee Justin B. has filed 8 SEC Form 4 filings (13 transaction rows) across 1 company, with disclosures dating back to 2025. 8 of those filings fall inside the rolling window. Most recent filing: Sep 14, 2026.

On the most recent filing, Klee Justin B. is listed as Co-Chief Executive Officer at Amylyx Pharmaceuticals, Inc. Inside the rolling window, Klee Justin B. reported no open-market purchases and 7 open-market sales totaling $4.0M in AMLX. The largest disclosed transaction in the window is a sale of 136,193 AMLX shares on Jan 15, 2026, worth $1.8M.

Companies traded

Other insiders at AMLX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$4.0M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
AMLXSale$980KSep 14SEC ↗
AMLXSale$424KMar 4SEC ↗
AMLXSale$228KFeb 4SEC ↗
AMLXSale$1.8MJan 20SEC ↗
AMLXSale$28KJan 20SEC ↗
AMLXSale$86KJan 8SEC ↗
AMLXSale$431KOct 2SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Klee Justin B. made?

Klee Justin B. has filed 8 SEC Form 4 filings (13 transaction rows) across 1 company since 2025.

Which companies does Klee Justin B. trade?

Klee Justin B. has filed SEC Form 4 disclosures for 1 company, including AMLX.

When was Klee Justin B.'s most recent SEC Form 4 filing?

Klee Justin B.'s most recent SEC Form 4 filing on Tracefour is dated Sep 14, 2026.

What is Klee Justin B.'s job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Klee Justin B. is listed as Co-Chief Executive Officer.

What is Klee Justin B.'s total buy and sell value in the current window?

Inside the rolling retention window, Klee Justin B. bought $0 and sold $4.0M based on SEC Form 4 filings.

What was Klee Justin B.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 136,193 AMLX shares on 2026-01-15, worth $1.8M, per SEC Form 4 filings.